### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Nancy J. Harper, et al.

Examiner: Oh, Taylor V.

APPLICATION NO.: Not Yet Known

Group Art Unit: 1624

FILING DATE: Concurrently Herewith

TITLE: SERTRALINE ORAL CONCENTRATE

Commissioner for Patents P.O. Box 1450 Alexandria, VA. 22313-1450

Sir:

### **PRELIMINARY AMENDMENT**

Prior to examination on the merits, please amend the application as follows:

### IN THE SPECIFICATION:

# Page 1, between lines 3 and 4, insert the following text:

-- This application is a continuation of Ser. No. 09/417,175, filed Oct. 11, 1999, which claims the benefit of Ser. No. 60/104,024, filed Oct. 13, 1998.--

## **REMARKS**

The subject application is a continuation of Ser. No. 09/417,175, filed Oct. 11, 1999, which claims the benefit of provisional Ser. No. 60/104,024, filed Oct. 13, 1998, and is filed to pursue the invention of claims 1-13. Applicant has inserted priority information on page 1 for the present application as required by 37 C.F.R. § 1.78.

If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicant's undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17, or to credit any overpayment, to Deposit Account No. 16-1445.

Respectfully submitted,

Date: February 3, 2004

A. David Joran / Attorney for Applicant(s)

Reg. No. 37,858

Pfizer Inc Patent Department 150 East 42nd Street – 5<sup>th</sup> Floor New York, NY 10017-5755 (212) 733-3381